NIAID participates in or funds many different consortia, clinical trial programs, networks, and research collaborations that help to move science forward. These are listed here, with new ones added all the time. Use the Search for Networks field to narrow your search.
The Accelerating Medicines Partnership is a public-private collaboration among the NIH, pharmaceutical companies, and non-profit organizations.
AccessClinicalData@NIAID is a cloud-based, secure data platform that enables sharing of and access to reports and data sets from NIAID COVID-19 and other sponsored clinical trials for the basic and clinical research community.
This NIH program supports optimizing adjuvant candidates; vaccine formulation and preclinical adjuvant pharmacology, toxicity, and efficacy studies.
The NIAID ACTG supports the largest network of expert clinical and translational investigators and therapeutic clinical trials units in the world.
In 2013, NIAID launched the Antibacterial Resistance Leadership Group (ARLG), a major clinical effort to address antibacterial resistance (AR).
Antiviral Drug Discovery (AViDD) program will be comprised of multidisciplinary Centers focused on the discovery and development of new antiviral drug candidates and lead series with the aim of generating a more robust pipeline of novel antivirals targeting the immediate threat of SARS-CoV-2 and providing antiviral drug candidates that might quickly pivot to address future viral outbreaks or pandemics.
The AADCRC program is the cornerstone of NIAID efforts to promote multidisciplinary basic and clinical research on asthma and allergic diseases.
The NIAID Atopic Dermatitis Research Network conducts clinical research research to learn more about skin infections associated with atopic dermatitis.
An overview of NIAID's Autoimmunity Centers of Excellence and its major areas of research focus.
An overview of the NIAID Biocontainment Laboratories including major focus areas and contact information.
The Bioinformatics and Computational Biosciences Branch drives innovation in biomedical informatics at NIAID for global health clinicians and researchers.
An overview of the NIAID Bioinformatics Resource Centers including contact information and major areas of focus.
The Center for Advanced Tissue Imaging (CAT-I) is a NIAID and NCI supported effort involving collaborative studies between experts in various laboratories.
CHAVI-ID are two consortiums established by NIAID to tackle the major scientific obstacles in the development of an effective HIV vaccine.
CIDI is a partnership between NIAID and Radiology and Imaging Sciences at the National Institutes of Health Clinical Center.
The Centers for AIDS Research (CFAR) program at NIH provides administrative and shared research support to enhance and coordinate AIDS research projects.
The NIAID Centers for HIV Structural Biology captured in unprecedented detail the 3-D structures of HIV components bound to human cellular components.
The NIAID CMCRC works to develop effective medical countermeasures for radiological or nuclear emergencies.
An overview of the NIAID Centers for Research in Emerging Infectious Diseases (CREID) including contact information and major focus areas.
NIAID established the Centers of Excellence for Influenza Research and Response (CEIRR) to study natural history, transmission, and pathogenesis of influenza and provide an international research infrastructure to address influenza outbreaks.
NIAID-supported translational activities range from very early discovery-based efforts to late-stage preclinical development.
The NIAID Clinical Islet Transplantation Consortium conducts studies of islet transplantation in patients with type 1 diabetes.
NIAID's Clinical Trials in Organ Transplantation program conducts clinical and associated mechanistic studies to improve outcomes in transplant recipients.
The NIAID Clinical Trials in Organ Transplantation in Children program focuses on the specific challenges associated with pediatric organ transplantation.
NIAID CIVICs is a network of research centers that work together to develop more durable, broadly protective and longer-lasting influenza vaccines.